Calcium antagonists or beta-blockers in chronic ischaemic left ventricular dysfunction?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Angina pectoris is prevalent in patients with severe left ventricular dysfunction (LVD), impacting clinical outcomes and healthcare costs.
• While angiotensin-converting enzyme (ACE) inhibitors improve survival in LVD patients, they do not significantly reduce anginal attack incidence.
• Current treatment for angina in severe LVD relies on nitrates, beta-blockers, and calcium channel blockers.

Purpose of the Study:

• To evaluate the role and limitations of beta-blockers in managing angina pectoris in patients with severe left ventricular dysfunction.

Main Methods:

• The abstract discusses findings from the Studies of Left Ventricular Dysfunction (SOLVD) and general pharmacological principles of beta-blocker action.
• Analysis of patient data regarding angina prevalence and tolerance to beta-blocker therapy based on ejection fraction and heart failure status.

Main Results:

• Beta-blockers effectively improve myocardial oxygen supply-demand balance and may slow LVD progression, contributing to improved survival post-myocardial infarction.
• However, beta-blockers can depress ventricular pump function, particularly when ejection fraction is below 35%.
• Full-dose beta-blocker tolerance is low in patients with severe LVD (30% without heart failure, 10% with heart failure).

Conclusions:

• Beta-blockers are valuable anti-anginal agents but their use in severe LVD is limited by potential cardiac depression and poor tolerance.
• Alternative or adjunctive therapies are necessary for angina management in this high-risk patient population.
• Beta-blockers do not address underlying mechanisms of some anginal attacks, such as coronary vasoconstriction.